GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (OTCPK:VTRLY) » Definitions » EV-to-FCF

VTRLY (Vitrolife AB) EV-to-FCF : 30.73 (As of Mar. 25, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Vitrolife AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vitrolife AB's Enterprise Value is $2,532.4 Mil. Vitrolife AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $82.4 Mil. Therefore, Vitrolife AB's EV-to-FCF for today is 30.73.

The historical rank and industry rank for Vitrolife AB's EV-to-FCF or its related term are showing as below:

VTRLY' s EV-to-FCF Range Over the Past 10 Years
Min: 23.71   Med: 48.3   Max: 186.31
Current: 28.94

During the past 13 years, the highest EV-to-FCF of Vitrolife AB was 186.31. The lowest was 23.71. And the median was 48.30.

VTRLY's EV-to-FCF is ranked worse than
53.14% of 382 companies
in the Medical Devices & Instruments industry
Industry Median: 27.355 vs VTRLY: 28.94

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-25), Vitrolife AB's stock price is $18.00. Vitrolife AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.359. Therefore, Vitrolife AB's PE Ratio (TTM) for today is 50.14.


Vitrolife AB EV-to-FCF Historical Data

The historical data trend for Vitrolife AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB EV-to-FCF Chart

Vitrolife AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.95 242.12 48.95 43.26 33.16

Vitrolife AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.26 37.50 31.82 46.21 33.16

Competitive Comparison of Vitrolife AB's EV-to-FCF

For the Medical Devices subindustry, Vitrolife AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrolife AB's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's EV-to-FCF falls into.



Vitrolife AB EV-to-FCF Calculation

Vitrolife AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2532.400/82.408
=30.73

Vitrolife AB's current Enterprise Value is $2,532.4 Mil.
Vitrolife AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $82.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vitrolife AB  (OTCPK:VTRLY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Vitrolife AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=18.00/0.359
=50.14

Vitrolife AB's share price for today is $18.00.
Vitrolife AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.359.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Vitrolife AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vitrolife AB Business Description

Traded in Other Exchanges
Address
Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.

Vitrolife AB Headlines

From GuruFocus

Q4 2022 Vitrolife AB Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q3 2023 Vitrolife AB Earnings Call Transcript

By GuruFocus Research 03-08-2024

Conference call interim report

By PRNewswire 10-10-2024

Vitrolife AB Capital Markets Day Transcript

By GuruFocus Research 03-08-2024

Q2 2021 Vitrolife AB Earnings Call Transcript

By GuruFocus Research 03-08-2024

Election committee for Vitrolife AB (publ)

By PRNewswire 10-04-2024

Q3 2021 Vitrolife AB Earnings Call Transcript

By GuruFocus Research 03-08-2024